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Abstract We have previously reported that tolbutamide pre-
vents the inhibition of gap junction communication in astrocytes.
Here, we show that tolbutamide increases gap junction commu-
nication and connexin 43 expression in poorly coupled C6 glioma
cells. The increase in communication is concurrent with the
inhibition of the rate of proliferation due to a block of the
progression of C6 glioma cells through the S phase of the cell
cycle. The effects of tolbutamide were quantitatively similar to
that found after the elevation of intracellular cAMP. Further-
more, the effects of tolbutamide and cAMP were additive. The
possible beneficial effect of tolbutamide on gene therapy for
gliomas is discussed. ß 2001 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Gap junction communication has long been proposed as a
mechanism required to maintain the control of cell growth [1].
In this context, we have recently shown that the inhibition of
gap junction communication triggers astrocyte proliferation
and the metabolic pathways required for nucleic acid synthesis
[2]. Furthermore, the neoplastic phenotype of several tumors
includes the absence of gap junction communication [3]. In
fact, several connexins, the proteins which form gap junction
channels, have been proposed as tumor suppressor proteins
[4]. For instance, the expression of connexin 43, the main
connexin in astrocytes [5], correlates inversely with the degree
of glioma malignancy [6^8] and the transfection of connexin
43 in glioma cells decreases their rate of growth [9,10]. There-
fore, the expression of connexin 43 and hence the establish-
ment of gap junction communication decrease glioma cell
proliferation.
Gliomas are the most common brain tumors and are gen-
erally highly malignant with a bad prognosis [11]. Because
traditional treatments such as chemotherapy or radiotherapy
have failed to improve this prognosis [12,13], new strategies
such as that based on gene therapy are currently being devel-
oped [14]. One of these approaches involves the herpes sim-
plex virus thymidine kinase (HSV tk) gene combined with
gancyclovir (GCV), currently in clinical trials [15]. GCV is
an antineoplasic drug that is only activated after phosphory-
lation, which takes place in cells transfected with the HSV tk
gene. Since current methods of transfection do not reach a
high percentage of cells, GCV is active only in a reduced
number of glioma cells. Cell communication through gap
junctions allows the di¡usion of the active form of GCV to
neighboring cells through the phenomenon known as the ‘by-
stander e¡ect’ [16,17]. Therefore, the higher the level of gap
junction communication between glioma cells, the higher the
e⁄ciency of HSV tk-GCV gene therapy, since active GCV
spreads to more extensive areas [18,19].
As described above, malignant glioma cells express low lev-
els of communication through gap junctions. The induction of
connexin expression in these tumoral cells could lead to two
bene¢cial e¡ects on tumor control, bystander e¡ect mediation
and tumor supression. Thus, the development of new strat-
egies to increase gap junction communication in glioma cells
may in£uence the outcome of cancer therapy with HSV tk-
GCV. We have previously reported that tolbutamide and oth-
er sulfonylureas increase gap junction communication in as-
trocytes treated with several gap junction inhibitors [20,21].
Consequently, in the present work we were prompted to in-
vestigate whether tolbutamide might increase gap junction
communication in C6 glioma cells and hence decrease the
exacerbated rate of proliferation.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium (DMEM), penicillin, strepto-
mycin, poly-L-lysine, tolbutamide, 2P-O-dibutyryladenosine 3P :5P-
cAMP (dbcAMP), 5-bromo-2P-deoxyuridine (BrdU), monoclonal
antibodies against BrdU, protease inhibitors, polyacrylamide, anti-
mouse Ig biotin, anti-mouse Ig FITC, avidin-peroxidase conjugate,
the AEC substrate staining kit, propidium iodide and Lucifer yellow
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were purchased from Sigma-Aldrich Chemical Co. (Madrid, Spain).
Fetal calf serum (FCS), DNase and trypsin were obtained from
Boehringer Mannheim (Barcelona, Spain). Monoclonal antibodies
against connexin 43 were from Chemicon International Inc. (Temecu-
la, CA, USA). Nitrocellulose sheets were from Bio-Rad (Madrid,
Spain). Other chemicals were purchased from Sigma-Aldrich Chem-
ical Co. (Madrid, Spain) or Merck (Barcelona, Spain).
2.2. Cell culture
Rat glioma C6 cells were cultured as previously described [22].
Brie£y, cells were cultured in DMEM supplemented with 7.5% (v/v)
FCS, penicillin (50 U/ml) and streptomycin (37.5 U/ml) on poly-L-
lysine-coated Petri dishes. Cells were maintained in culture for 5 days
until con£uence. 24 h before the experiments, the culture medium was
replaced by fresh serum-free DMEM.
2.3. Assessment of junctional communication
Gap junction permeability was determined by the scrape-loading/
dye transfer technique described by El-Fouly et al. [23], adapted to
our experimental conditions [22]. Brie£y, the culture medium was
removed and cells were washed with an ionic solution (130 mM
NaCl, 2.8 mM KCl, 1 mM CaCl2, 2 mM MgCl2 and 10 mM HEPES,
pH 7.2) and preincubated at room temperature in the ionic solution.
After 10 min, this solution was removed and cells were further incu-
bated in the same ionic solution without Ca2 [24] for 2 min. Scrape-
loading was performed by scraping the cell layer with a broken razor
blade in the Ca2-free ionic solution containing 1 mg/ml of Lucifer
yellow CH (Sigma), a highly £uorescent dye that passes through gap
junctions from loaded cells to neighboring ones, but not through the
plasma membrane. After 2 min, the dye solution was removed and the
cells were carefully washed with excess ionic solution. 8 min after
scraping, £uorescence photomicrographs were captured with a digital
video camera (Leica DC100) connected to an inverted £uorescent
microscope equipped with appropriate ¢lters (Diaphot, Nikon).
To estimate gap junction permeability, six photomicrographs of the
center of the dish were taken. Data were obtained by measuring the
£uorescent areas of the images using image-analyzer software (NIH
Image, kindly supplied by Wayne Rasband, NIH, Bethesda, MD,
USA).
2.4. Western blotting
Connexin 43 expression was followed by Western blotting as de-
scribed previously [2]. Proteins were extracted from the cells using 2%
sodium dodecyl sulfate (SDS) in 5 mM Tris^Cl, pH 6.8, containing
2 mM ethylene glycol-bis[L-aminoethyl ether]-N,N,NP,NP-tetraacetic
acid (EGTA), 2 mM ethylenediaminetetraacetic acid (EDTA), 2 mM
phenylmethylsulfonyl £uoride, 0.5 Wg/ml antipain, 0.5 Wg/ml pepstatin,
0.5 Wg/ml amastatin, 0.5 Wg/ml leupeptin, 0.5 Wg/ml bestatin and 0.5
Wg/ml of trypsin inhibitor. The protein extract (90 Wg) was applied to
a 10% SDS^polyacrylamide gel under reducing conditions and then
transferred to a nitrocellulose sheet, as described [25]. The nitrocellu-
lose sheet was blocked with 10% fat-free dried milk in phosphate
bu¡ered saline (PBS) and then exposed to monoclonal connexin 43
antibody (1:1000) for 12 h overnight. Anti-mouse Ig biotin (1:1000)
was applied for 4 h, followed by conjugated avidin-peroxidase
(1:2000) for 1 h. The AEC staining substrate kit, prepared according
to the manufacturer’s instructions, was then applied for 10 min.
Stained nitrocellulose sheets were scanned and the intensity of the
bands analyzed using image-analyzer software (NIH Image).
2.5. BrdU labeling for measurement of DNA synthesis
Cell proliferation was determined by counting the number of cells
incorporating BrdU, as previously described [2]. C6 glioma cells were
incubated with 10 WM BrdU for 24 h prior to the immunocytochem-
ical detection of this thymidine analogue. Then, C6 cells were incu-
bated with the monoclonal antibody against BrdU (1:100) in PBS
containing 0.1% Triton X-100 for 12 h. After washing, C6 glioma
cells were incubated with anti-mouse Ig FITC (1:100) for 24 h. The
total number of cells and proliferative nuclei were counted in at least
10 ¢elds per Petri dish using image-analyzer software (NIH Image).
Each experiment was carried out in six separate Petri dishes.
2.6. Cell cycle studies
The C6 glioma cell cycle was analyzed by £ow cytometry following
the method described by Vindelov et al. [26] with minor modi¢cations
[27]. Brie£y, cells were harvested and the cell suspensions were incu-
bated with a sodium citrate bu¡er solution containing 0.05% (w/v)
RNAse and 0.1% (w/v) trypsin inhibitor for 10 min. Then, 1.5 ml
of the same solution containing 0.021% (w/v) propidium iodide was
added and incubation was continued for 15 min at room temperature.
At least 20 000 events were analyzed for each experiment on a FACS-
can £ow cytometer. For the calculation of the distribution of the cells
along the di¡erent cell cycle phases ModFit mathematical model was
used.
2.7. Statistical analyses
Statistical analyses were performed using Student’s t-test.
3. Results
3.1. Tolbutamide increases gap junction permeability and
connexin 43 expression in C6 glioma cells
To test the e¡ect of tolbutamide on gap junction commu-
nication in C6 glioma cells, scrape-loading experiments were
carried out and the level of expression of connexin 43 was
followed by Western blotting. It is well established that the
increase in intracellular levels of cAMP upregulates gap junc-
tion communication in C6 glioma and other tumoral cells [28^
30]. The e¡ect of tolbutamide was therefore studied in parallel
and compared with that of dbcAMP. Similarly to other tu-
Fig. 1. E¡ect of tolbutamide and dbcAMP on gap junction perme-
ability among C6 glioma cells. Where stated, C6 glioma cells were
preincubated with 400 WM tolbutamide (tolb) for 30 min, 1 mM
dbcAMP for 24 h or 1 mM dbcAMP for 24 h plus 400 WM tolbuta-
mide for 30 min. Tolbutamide was maintained at the same concen-
tration for the rest of the experiment. a^d: Gap junction permeabil-
ity was determined by the scrape-loading technique. Loading was
performed from the right side of the photographed ¢eld. e: The
£uorescent area was quanti¢ed; the results are means þ S.E.M.
(n = 12). Statistical di¡erences as compared to controls are given as
***P6 0.001 and those compared to the presence of dbcAMP alone
as ##P6 0.01. Bar = 50 Wm.
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moral cells, C6 glioma cells are characterized by a low level of
communication through gap junctions (Fig. 1a, see also [9]).
In this work we show that tolbutamide increases gap junction
communication between C6 glioma cells (Fig. 1b). Thus, using
C6 glioma cells the scrape-loading experiments revealed that
Lucifer yellow di¡usion is restricted to the ¢rst row of cells
(Fig. 1a). In the presence of tolbutamide, however, Lucifer
yellow reached approximately three rows of C6 cells (Fig.
1b). Our results indicated that the presence of tolbutamide
increased communication through gap junctions by about
20%, as judged by quanti¢cation of the £uorescent areas ob-
tained after scrape-loading experiments (Fig. 1e). Our results
(Fig. 1c and e) con¢rm that dbcAMP increases gap junction
permeability in C6 glioma cells [19] and also show that the
e¡ect of tolbutamide on gap junction communication is sim-
ilar to that obtained with dbcAMP. In addition, when C6 cells
were incubated with tolbutamide plus dbcAMP, the commu-
nication through gap junction increased by about 30% as
compared to the controls and this increase was signi¢cantly
higher than that obtained with dbcAMP alone (Fig. 1d and e).
Western blot analyses (Fig. 2) revealed that tolbutamide
increased the expression of connexin 43, the protein forming
the gap junction channel [5], by about 40%. Our results show
Fig. 2. E¡ect of tolbutamide and dbcAMP on connexin 43 expres-
sion in C6 glioma cells. Where stated, C6 glioma cells were pre-
treated with 400 WM tolbutamide (tolb), 1 mM dbcAMP or 400 WM
tolbutamide plus 1 mM dbcAMP. After 24 h, Western blotting of
connexin 43 (Cx43) was carried out (upper panel). The intensity of
the bands was quanti¢ed (lower panel) with a detection limit of
50.8 þ 6.2 arbitrary units. Results are means þ S.E.M. (n = 4) and are
expressed in arbitrary units. The coe⁄cient of analytical variation
was always lower than 14%. Statistical di¡erences as compared to
controls are given as ***P6 0.001 and **P6 0.01 and those com-
pared to the presence of dbcAMP alone as ##P6 0.01.
C
Fig. 3. E¡ect of tolbutamide and dbcAMP on the rate of C6 glioma
cell proliferation. Where stated, C6 glioma cells were pretreated
with 400 WM tolbutamide (tolb), 1 mM dbcAMP or 400 WM tolbu-
tamide plus 1 mM dbcAMP for 18 h. These treatments were main-
tained at the same concentration for the rest of the experiment.
Cells were further incubated with 10 WM BrdU for 24 h. Incorpora-
tion of BrdU was determined by immunocytochemistry. a^d:
Immunocytochemistry showing only £uorescent BrdU-positive nu-
clei. Note that the presence of tolb and dbcAMP reduced the num-
ber of BrdU-positive nuclei per ¢eld. This e¡ect was stronger when
both agents were added together. e: Percentages of cells incorporat-
ing BrdU. f: Number of cells incorporating BrdU per ¢eld. g: Total
number of cells per ¢eld. Results are means þ S.E.M. from at least
eight experiments. Statistical di¡erences as compared to controls are
given as ***P6 0.001. Statistical di¡erences as compared to the
presence of dbcAMP alone as ###P6 0.001. BrdU, bromodeoxyuri-
dine. Scale bar = 50 Wm.
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that the increase in connexin 43 expression promoted by tol-
butamide was very similar to that found with dbcAMP (Fig.
2). In addition, the expression of connexin 43 was nearly
doubled by the presence of tolbutamide plus dbcAMP in the
culture medium (Fig. 2).
3.2. Tolbutamide decreases the rate of C6 glioma cell
proliferation
C6 glioma cell proliferation was estimated by quantifying
BrdU incorporation by immunocytochemistry (see Fig. 3a^d,
as representative experiments). The presence of tolbutamide
clearly decreased the number of BrdU-positive nuclei (white
nuclei ; Fig. 3b). The percentage of C6 cells incorporating
BrdU decreased by about 10% in the presence of tolbutamide
(Fig. 3e). As has been previously reported [31], the presence of
dbcAMP inhibited C6 glioma cell proliferation (Fig. 3c and
e). Our results show that the e¡ect of dbcAMP on C6 glioma
cell proliferation was very similar to that obtained with tol-
butamide (Fig. 3e). Furthermore, the presence of tolbutamide
plus dbcAMP further decreased (by about 30%) the percent-
age of cells incorporating BrdU (Fig. 3d and e). It should be
mentioned that the decrease in proliferation promoted by tol-
butamide, dbcAMP and dbcAMP plus tolbutamide was high-
er than the above mentioned. Indeed, the number of cells
incorporating BrdU per ¢eld was signi¢cantly decreased by
the presence of tolbutamide, dbcAMP and dbcAMP plus tol-
butamide: about 22, 33 and 46%, respectively (Fig. 3f). The
di¡erences found between these results are due to the fact that
the presence of tolbutamide, dbcAMP and tolbutamide plus
dbcAMP signi¢cantly decreased the number of cells per ¢eld
by about 12.5, 24 and 21% respectively (Fig. 3g), suggesting
that they induced C6 glioma cell death.
In order to know which cell cycle phase was a¡ected by
tolbutamide, cells were analyzed by £ow cytometry. Our re-
sults indicated that the presence of tolbutamide reduced the
percentage of cells in the G2^M phases of the cell cycle by
about 25% (Fig. 4a, b and e), with a concomitant increase in
those in S phase (from 3.59 þ 0.39 to 6.84 þ 0.37%; P6 0.001).
The presence of dbcAMP reduced the percentage of S phase
cells (from 3.59 þ 0.39 to 2.10 þ 0.34%; P6 0.05), while the
percentage of cells in the G0^G1 phases increased (by about
12%). Treatment with tolbutamide plus dbcAMP decreased
the number of cells in the G2^M phases (by about 26%) while
it increased those in G0^G1 phases (by about 14%).
4. Discussion
We have previously reported that tolbutamide and other
sulfonylureas prevent the inhibition of gap junction commu-
nication caused by gap junction uncouplers in astrocytes
[20,21]. Here, we show that tolbutamide also increases gap
junction permeability in the poorly coupled C6 glioma cells
(Fig. 1a and b). In addition, tolbutamide increased the expres-
sion of connexin 43 (Fig. 2), the protein forming the gap
junction channel [5]. The e¡ect of tolbutamide on gap junc-
tion communication was quantitatively very similar to that
found with dbcAMP (Figs. 1 and 2), a well-known activator
of gap junction communication in several tumoral cells, in-
cluding C6 glioma cells [28^30]. However, our ¢ndings indi-
cate that the pathways followed by tolbutamide and dbcAMP
to increase gap junction communication and connexin 43 ex-
pression must be di¡erent, since their e¡ects were additive
(Figs. 1 and 2). Therefore, these results clearly indicate that
the combination of these agents could result in an important
increase in both the expression of connexin 43 and the com-
munication through gap junction in C6 glioma cells. Since the
e⁄ciency of HSV tk-GCV gene therapy for gliomas depends
on the level of gap junction communication among tumoral
cells (for a review see [16,32]), it is reasonable to suggest that
tolbutamide, a clinically tolerable drug, either alone or in
combination with agents that promote an increase in the in-
tracellular levels of cAMP could act as coadjuvants for HSV
tk-GCV therapy by increasing the spread of the active anti-
neoplasic form of GCV.
Gap junction communication not only improves gene ther-
apy but also plays an important role in tumor suppression.
Thus, the transfection of connexin 43 in glioma cells decreases
their rate of growth [9,10]. Moreover, an elevation in intra-
cellular cAMP levels induces glioma cell di¡erentiation, char-
acterized by the increase in gap junction communication and
the decrease in proliferation [31]. Consequently, the establish-
ment of gap junction communication in the poorly coupled
cells of gliomas recovered the control of cell growth. In agree-
ment with this, our results show that together with increasing
gap junction communication and connexin 43 expression
Fig. 4. E¡ect of tolbutamide and dbcAMP on the C6 glioma cell
cycle analyzed by £ow cytometry. Where stated, C6 glioma cells
were pretreated with 400 WM tolbutamide (tolb), 1 mM dbcAMP or
400 WM tolbutamide plus 1 mM dbcAMP. After 48 h cells were
harvested and their nuclei stained with propidium iodide. a^d:
20 000 events were used to analyze the cell cycle by £ow cytometry.
Note that the presence of tolbutamide reduced the peak correspond-
ing to cells in the G2^M phases of cell cycle (gray line). e: Integra-
tion of the areas corresponding to each phase of the cell cycle. Re-
sults are expressed as percentage of cells found in the di¡erent cell
cycle phases and are means þ S.E.M. of ¢ve to six experiments. Sta-
tistical di¡erences as compared to controls are given as
***P6 0.001; **P6 0.01; *P6 0.05.
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(Figs. 1 and 2), tolbutamide signi¢cantly decreases the rate of
C6 glioma cell proliferation and this e¡ect was additive with
that of cAMP (Fig. 3b, c and e). In agreement with this,
di¡erent cell cycle phases were a¡ected by these two agents
(Fig. 4). Thus, whereas dbcAMP decreased the percentage of
cells in the S phase, correlating with an accumulation of C6
glioma cells in the G0^G1 phases, tolbutamide decreased pro-
liferation by inhibiting progression through the S phase of the
cell cycle (Fig. 4). Indeed, tolbutamide signi¢cantly decreased
the percentage of cells in the G2^M phases coinciding with an
increase in the number of cells in the S phase.
Our results are insu⁄cient to recommend the use of tolbu-
tamide or other sulfonylureas for the treatment of gliomas.
Nevertheless, two potential bene¢cial e¡ects of tolbutamide as
a coadjuvant for antineoplasic therapy should be mentioned.
First, tolbutamide could improve the e⁄ciency of gene ther-
apy since it increases gap junction communication and hence
the ‘bystander e¡ect’. Second, tolbutamide inhibits the rate of
glioma cell proliferation which is the goal of antineoplasic
drugs. Finally, the e¡ect of tolbutamide takes place through
transduction signals other than cAMP, allowing its combina-
tion with agents which increase intracellular concentrations of
cAMP.
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